vimpat
| Name | VIMPAT® (Lacosamide) |
| Description | VIMPAT® is an antiepileptic drug (functionalized amino acid). The antiepileptic effects of which appear to be due to a novel mode of action, namely the selective enhancement of slow inactivation of voltage-gated sodium channels. |
| Indication |
VIMPAT® (Lacosamide) is approved as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents and children from 4 years of age with epilepsy. |
| Strengths |
VIMPAT® (Lacosamide) film coated tablets (50, 100, 150 and 200 mg), syrup 200ml bottles (10 mg/ml) and IV solution for infusion (10 mg/ml). |
| Regulatory Status |
EMA approved: Film-coated tablets and Solution for infusion in August 2008. Syrup 10 mg/ml in February 2012. FDA approved: Film-coated tablets and Solution for infusion in October 2008. Oral Solution 10 mg/ml approved in April 2010. VIMPAT® Tablets are registered in KSA, Kuwait, UAE, Qatar, Bahrain, Oman & Lebanon VIMPAT® Solution for Infusion is registered in KSA, Kuwait, UAE, Qatar, Bahrain, Oman & Lebanon VIMPAT® Syrup is registered in KSA, Kuwait, UAE, Qatar, Bahrain, Oman & Lebanon |
| Business Partner | UCB |
